MDxHealth and Queensland University of Technology Collaborate on Oral Cancer Liquid Biopsy Test
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, June 19, 2017 - MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a scientific agreement with QUT bluebox, the commercialization arm of the Queensland University of Technology (QUT), to develop a liquid biopsy epigenetic assay for the early detection of oral cancer.
Oral cancer has a significant global incidence with approximately over 20,000 cases diagnosed annually in the US alone. Early detection is key to survival, but noticeable symptoms appear at a more advanced stage when there is a less favorable prognosis. Currently, there are no US screening guidelines for head and neck cancers or proven blood or saliva-based diagnostic tests.
"Our test is expected to facilitate much earlier detection of oral cancer and potentially precancerous lesions by a variety of specialties including general practioners, oncologists and dentists," said Associate Prof. Dr. Chamindie Punyadeera from QUT's School of Biomedical Sciences and Institute of Health and Biomedical Innovation (IHBI), lead investigator on this project. "After collecting a saliva swab, samples will be sent to a lab or tested on site to determine if a patient requires clinical follow up."
The test evaluates abnormal DNA methylation changes which is an early event seen in tumor progression. Methylation of DNA is one way that cells regulate gene activity and abnormal methylation indicates a patient may have a higher risk of developing cancer.
"A simple and fast point of care test could help dentists to rule-out oral cancer while you have your dental checkup," said Dr. Jan Groen, CEO of MDxHealth. "This scientific collaboration is an opportunity for both MDxHealth and QUT to leverage existing know-how to develop a ground-breaking oral cancer test that will improve overall survival for thousands of patients."
Under the terms of the agreement, MDxHealth will collaborate with QUT to evaluate and develop the test and MDxHealth will have the first option to license the commercial diagnostics rights. Proceeds will be used to support MDxHealth's R&D pipeline for diagnostics in urologic cancers and to support further research and translational activities at QUT and IHBI.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
QUT bluebox is Queensland University of Technology's innovation, venture and investment company. QUT bluebox helps the QUT community get their ideas and research out into the real world, and connect industry with research and new ventures to make a meaningful impact. QUT bluebox's work on this project included IP management, Go To Market Funding, licensing, industry engagement, commercialisation advice and support. For more information, visit https://www.qutbluebox.com.au.
For more information:
Shalon Roth, EVP Corporate Communications
+44 (0)7393 906278
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.